How big is Journey Medical Corp.?

As of Jun 18, Journey Medical Corp. has a market capitalization of 147.00 million and reported net sales of 56.25 million with a net profit of -8.30 million over the latest four quarters. Shareholder's funds are at 20.07 million, and total assets are 80.24 million as of Dec 24.

As of Jun 18, Journey Medical Corp. has a market capitalization of 147.00 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 56.25 million, while the sum of Net Profit for the same period is -8.30 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 20.07 million and Total Assets at 80.24 million.

What does Journey Medical Corp. do?

Journey Medical Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $13 million and a net loss of $4 million as of March 2025. It has a market cap of $147 million and key metrics indicate it is currently loss-making with no dividend yield.

Overview:<BR>Journey Medical Corp. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 13 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 147.00 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.19 <BR>Return on Equity: -43.77% <BR>Price to Book: 6.82<BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Journey Medical Corp.?

Is Journey Medical Corp. overvalued or undervalued?

As of November 12, 2024, Journey Medical Corp. is considered a risky investment due to its overvaluation and poor financial metrics, including a Price to Book Value of 7.99 and a negative EV to EBITDA ratio of -22.82, despite a strong year-to-date return of 85.93%.

As of 12 November 2024, the valuation grade for Journey Medical Corp. has moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued given its negative financial metrics, including a Price to Book Value of 7.99 and a troubling EV to EBITDA ratio of -22.82. Additionally, the Return on Capital Employed (ROCE) stands at -44.88%, reflecting significant inefficiencies in generating returns from capital investments.<BR><BR>In comparison to peers, Journey Medical Corp.'s valuation ratios are less favorable; for instance, Fortress Biotech, Inc. has a more manageable EV to EBITDA of -0.87, while Sol-Gel Technologies Ltd. shows an EV to EBITDA of -11.11. Despite the company's strong year-to-date return of 85.93% compared to the S&P 500's 12.22%, the overall financial health suggests that the stock is not a sound investment at its current price of 7.27.

Is Journey Medical Corp. technically bullish or bearish?

As of August 29, 2025, Journey Medical Corp. has a mildly bullish technical trend, supported by monthly bullish indicators and strong year-to-date performance of 85.93%, significantly outperforming the S&P 500's 12.22%.

As of 29 August 2025, the technical trend for Journey Medical Corp. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are mildly bearish, while the monthly MACD and KST are bullish. The daily moving averages indicate a mildly bullish stance, and the Bollinger Bands show a bullish trend on the monthly timeframe. However, both the weekly and monthly Dow Theory and OBV indicate no trend. <BR><BR>In terms of performance, Journey Medical Corp. has outperformed the S&P 500 significantly year-to-date with a return of 85.93% compared to the S&P 500's 12.22%. Over the past year, the stock also shows a strong return of 41.99% against the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, driven by the monthly bullish indicators and strong multi-period returns.